Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies’ “Alumni in Action.” The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the long term plans of our company
Seeking Alpha recently covered our work with Twist Bioscience on novel antibody discovery.
EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.
Brett Averso (CTO, EVQLV) and Bhoomika Kumar (SciTech intern, EVQLV) teamed up to provide a high-level overview of how EVQLV’s evolutionary algorithm works.
EVQLV’s CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more.
Our CEO was recently asked how far away is fully computational drug discovery and development. This isn’t an easy question to answer and Andrew doesn’t provide an exact date. However, he does provide interesting insight into the progress we’ve made and the challenges ahead.
EVQLV CEO, Andrew Satz, explains that while speed is important, it can also be dangerous, and is certainly not the only reason we’ve chosen a computational approach to drug discovery.
Andrew Satz, CEO of EVQLV, explains how our technology works, with specific attention to our progress on COVID-19.
EVQLV’s very own Andrew Satz (CEO and CO-Founder) was a guest on the M2 Techcast of MITechNews.com with Mike Brennan and Matt Roush. He discussed our work on coronavirus, what is and isn’t artificial intelligence, the application of AI, and our mission at EVQLV.
BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
EVQLV uses artificial intelligence (AI) to discover and optimize novel biologics. Our algorithm uses an evolutionary approach with applied external pressures to generate candidates. There’s a lot more to it, but we thought you might enjoy a taste of our “secret sauce.”
We’re not sharing this information to scare, but instead to inform on the challenges the healthcare industry is facing. With that in mind, below we report on 21 innovative efforts from leading and emerging players in the biotech industry to combat the COVID-19 pandemic.